CDMO Acquisition
Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand its Biologics Offering in the U.S.
Recipharm AB
PR-M02-22-17Feb 18, 2022
mRNA Vaccine Manufacturing
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
Mark Bamforth; Dave Stevens
Arranta Bio
PAO-01-22-R250-04Jan 26, 2022
mRNA Manufacturing
Serving an Accelerated Market with mRNA Production
Mark Bamforth
Arranta Bio
PAO-11-21-CL-06Dec 08, 2021
Investing in mRNA Production
Michael Wourms
Arranta Bio
PA766Nov 22, 2021
mRNA Manufacturing
Limiting Risk In mRNA Development and Production
Doug Kennedy
Arranta Bio
PAO-11-21-CL-05Nov 22, 2021
mRNA Manufacturing
Integrating a Fragmented mRNA Supply Chain
Dave Stevens
Arranta Bio
PAO-11-21-CL-04Nov 22, 2021
Sale
Arranta Bio Announces Completion of Sale of Florida Site and Progress on $150M Investment Plan to Expand Development and Commercial Manufacturing Services
Arranta Bio
PA775Nov 16, 2021
mRNA
Integrated Support Facilitates mRNA Product Development and Commercialization
Michael Wourms; Dave Stevens
Arranta Bio
PAO-10-21-CL-15Oct 26, 2021
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Aaron B. Cowley, Ph.D.; Nicole O'Brien, Ph.D.
ReciBioPharm
PAO-09-21-CL-11Sep 28, 2021
mRNA Vaccines
Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-Ready GMP Facility
Arranta Bio
PR-M09-21-05Sep 23, 2021
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
Aaron B. Cowley, Ph.D.; Judith Bodette; Brian Duffy
ReciBioPharm
PAO-06-21-CL-10Jun 25, 2021
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
Aaron B. Cowley, Ph.D.; Melanie Cerullo; Jeff Heiser
ReciBioPharm
PAO-06-21-CL-05Jun 14, 2021
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
Arranta Bio
PR-M03-21-002-1066Mar 08, 2021
The Road to 2021
Road to 2021 Day 3: Scotland & England
Nigel Walker
Nice Insight
PAO-04-22-R221-30Jan 01, 2021
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Susan Surabian; Melanie Cerullo
Arranta Bio
PAP-Q4-20-CL-002Dec 09, 2020
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
Arranta Bio
PAP-Q4-20-RT2-007Dec 09, 2020
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
Aaron B. Cowley, Ph.D.
ReciBioPharm
PAP-Q3-20-CL-004Sep 29, 2020
Design Logic
Experience to Solve Your Microbiome Challenges
Nice Insight
PAP-Q3-20-NI-010Sep 29, 2020
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
Arranta Bio
PAP-Q3-20-RT2-009Sep 29, 2020
Capacity Expansion
Arranta Bio Announces Mechanical Completion of Commercial-Ready Capacity for Advanced Biologics
Arranta Bio
PR-M09-20-30Sep 28, 2020